»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Toremifene CAS 89778-26-7 ChlortaMoxifen Z-ToreMifene C08166 manufacturer

5th

Gold Index: 88356

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Toremifene CAS 89778-26-7 ChlortaMoxifen Z-ToreMifene C08166

Toremifene CAS 89778-26-7 ChlortaMoxifen Z-ToreMifene C08166 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C32H36ClNO8
Production Capacity: 2 Ton/year
Delivery Date: within 7 days
Specification: CP/USP/EP
Melting point: 405.96
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Molecular Formula: C26H28ClNO
Appearance: White crystal
Molecular Weight: 405.96

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body.

Toremifene ( CAS: 89778-26-7 )


Item

Index

Molecular Formula

C26H28ClNO

Molecular Weight

405.96

Specification

CP/USP/EP

Appearance

White crystal

Melting point

405.96


Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in theUnited   Statesunder the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.


In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008.


An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009, and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: